The global insulin aspart market was valued at USD 3.5 billion in 2025 and is expected to reach USD 3.7 billion in 2026. By 2033, the market is projected to reach USD 5.0 billion, expanding at a 4.6% CAGR from 2026 to 2033, according to Grand View Research. North America accounted for the largest revenue share of 41.5% in 2025, while Asia Pacific is anticipated to record the fastest...

The global insulin aspart market is gaining steady momentum as the worldwide burden of diabetes continues to increase. Rising obesity levels, sedentary lifestyles, aging populations, and improving diagnosis rates are expanding the number of patients requiring effective insulin-based therapies. As a rapid-acting insulin analog, insulin aspart plays an important role in mealtime glucose...